When drug trials go terribly wrong

THS reader Christopher Lane brought this article to my attention, and asked me to forward it on to my readers. Yet another tragic consequence of dangerous and overused psychiatric drugs.

Mary Weiss, a mother in Minnesota, was one such person who wrote me last month. I’d been on the radio, talking about issues tied to my book. Ms. Weiss wrote an email afterwards, telling me about her son, Dan Markingson, who’d been diagnosed with schizophrenia, though she herself has serious doubts that the diagnosis was accurate.

Her son was encouraged to participate in a clinical trial at the University of Minnesota and other campuses comparing Seroquel, Risperdal, and Zyprexa for schizophrenia, schizoaffective disorder, and schizophreniform disorder, a loosely defined diagnosis for people suffering from “mood disorders with psychotic features.” The trial was sponsored by AstraZeneca, maker of Seroquel, which put the researchers and university in an obvious conflict of interest. Dan was given 800 mg of the drug.

Over 70% of patients in the trial dropped out. But Dan was strongly dissuaded from doing so and remained in it for five months. He’d been given a directive warning that if he failed to continue in the trial, he would be put in a regional treatment center. His mother did not know about the directive until it was too late.

Follow this link to read the full story.

Related posts:

1. Study reveals doubt on cholesterol drug A new study has shaken the already shaky hypothesis that cholesterol causes heart disease to...
2. When it comes to drug claims, skepticism is healthy Drug companies make $285 billion a year selling their products. Can we trust them to...
3. Placebos as effective as antidepressants Recent studies on the efficacy of antidepressant drugs revealed that selective serotonin reuptake inhibitors (SSRIs),...
4. Drugs, money & kids: a dangerous mix An investigation revealed that a world-renowned child psychiatrist lied about money he received from drug...
5. Antidepressants not as effective as research suggests A new report shows that findings from clinical studies used to gain FDA approval of...